Gregory Friedman

Has grant

Professor

The University of Alabama

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Gregory Friedman is a faculty member at The University of Alabama at Birmingham, United States. His research primarily focuses on pediatric oncology, specifically exploring innovative treatments for high-grade gliomas and the application of oncolytic virotherapy. Recent publications highlight his work on combining therapies such as CAR T cell treatments and immunotherapies for malignant brain tumors.

Recent Grants

Grant: Close

Overcoming Immunotherapy Challenges in Pediatric Brain Tumors

Open Date: 2021-11-01

Close Date: 2024-11-01

Grant: Close

Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18.

Open Date: 2019-09-15

Close Date: 2022-08-31

Grant: Close

Engineered Oncolytic Herpes Simplex Virotherapy for Medulloblastomas

Open Date: 2016-07-01

Close Date: 2017-06-30

Grant: Close

Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)

Open Date: 2016-04-25

Close Date: 2019-03-31

Grant: Close

Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors

Open Date: 2015-07-15

Close Date: 2018-07-14

Articles (19)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gregory Friedman

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors

Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma

Next-generation CAR T cell therapies for glioblastoma

Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma.

The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.

Intracranial stimulation for brain cancer—The case for implantable, intracranial tumor treating fields

Positioning Transclival Tumor-Treating Fields for the Treatment of Diffuse Intrinsic Pontine Gliomas.

Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.

Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma.

Machine Learning in the Classification of Pediatric Posterior Fossa Tumors: A Systematic Review

Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers.

Immunotherapy approaches for the treatment of diffuse midline gliomas.

Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression

Clinical advances in oncolytic virotherapy for pediatric brain tumors.

Targeting oncometabolism to maximize immunotherapy in malignant brain tumors.

Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy.

Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

Collaborators (13)

Sumientra Rampersad

Jamie Aye

Michael Brown

James M. Markert

Elizabeth Beierle

Christopher D. Willey

Kyung-Don Kang

Casey Jarvis

Eric Thompson

Florian Gessler

Takumi Kumai

Sanjay Prabhu

Walid I. Essayed

Make your next move.